Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I got in the other day with 2.5k @ 5.38
~ $ASTX ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$ASTX has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "ASTX" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "ASTX": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ASTX ~
Search Ihub for "ASTX" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ASTX ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
c
Oh yes! been a great trading vehicle for me
Nice bruddah. Some serious potential in this imo.
$ASTX Buy Rating Friday ASTX +6.8% (initiated with a Buy at Brean
We nailed Both calls of the daily 200 ma support weeeeeeeeeeeeeeeeeeee
We Rock Higher! Manic Stock Alerts all over $ASTX Since last november!
ManicTrader Member Profile ManicTrader Member Level
Tuesday, July 02, 2013 1:33:22 AM
Re: cha-ching post# 12821
Post # of 12898
$ASTX Alert 4.35, Ready for another Run. Check it. Coming off the daily 200ma support. Might see a little pull back after hitting the 20day ma,
ManicTrader Member Level
Tuesday, November 20, 2012 1:07:37 PM
Re: None
Post # of 12898
$ASTX 2.44 Alert, 2.15 support here
~ $ASTX ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!
$ASTX has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~
For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~
What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~
To find other similar posts of "ASTX" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "ASTX": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ASTX ~
Search Ihub for "ASTX" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ASTX ~
For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~
Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~
c
Astex Pharmaceuticals Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)
Correlation of Biomarkers and DNA Methylation to Clinical Responses
DUBLIN, Calif., June 20, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that updated clinical data from the dose escalation part of a randomized phase 1/2 clinical trial of subcutaneous SGI-110, a novel hypomethylating agent, in patients with relapsed/refractory acute myelogenous leukemia (r/r AML) will be presented in an oral session during the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam, Netherlands September 27 - October 1, 2013.
Abstract #3.601, "Study of the correlation of baseline biomarkers and DNA demethylation to clinical responses in a phase 1/2, randomized study of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML)," has been selected for oral presentation in the "Hematological Malignancies" proffered paper session on September 28th at 11:15 am CEST.
The presentation will include details of r/r AML responses in the dose escalation part of the trial, and the correlation between these responses and several baseline and DNA methylation biomarkers.
About SGI-110:
SGI-110 is a novel small molecule, DNA-hypomethylating agent administered as a single small volume subcutaneous injection. SGI-110 demonstrated activity in restoring silenced tumor suppressor gene expression in cancer cells by reversal of DNA methylation and inducing responses in previously treated MDS and AML patients. SGI-110 is wholly owned by Astex Pharmaceuticals.
About the SGI-110 study in MDS and AML patients (Study SGI-110-01):
The SGI-110-01 trial is a randomized phase 1/2 study in patients with MDS and AML. The trial completed its phase 1 dose escalation segment (Part A) and the results were presented at the December 2012 ASH meeting, "Results From the Dose Escalation Phase of a Randomized Phase 1-2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML." A copy of this presentation is available on the Astex Pharmaceuticals website, www.astx.com, in the pipeline, presentations and publications section.
This study is currently in the phase 2 dose expansion segment (Part B) of the study. Its primary objective is to estimate overall response rates in four patient cohorts (relapsed/refractory AML; relapsed-refractory MDS; front-line elderly AML not suitable for induction chemotherapy; and front-line MDS). Secondary objectives include estimating the incidence and severity of adverse events, duration of response, overall survival, and the correlation of demethylation, genetic, and pharmacologic biomarkers with response. Additional information about the study can be found online at clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01261312.
Astex Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
Apr 29 2013, 22:30 | about: ASTX
Executives
Timothy L. Enns - Senior Vice President of Investor Relations, Business Development & Corporate Communications
James S. J. Manuso - Chairman and Chief Executive Officer
Mohammad Azab - Chief Medical Officer
Harren Jhoti - Co-Founder, Chief Executive Officer and Director
Martin Buckland - Chief Business Officer and Director
Michael Molkentin - Chief Financial Officer, Principal Accounting Officer and Corporate Secretary
Analysts
Michael J. Yee - RBC Capital Markets, LLC, Research Division
Michael G. King - JMP Securities LLC, Research Division
Jason Zhang - Edison Investment Research Limited
Boris Peaker - Rodman & Renshaw, LLC, Research Division
Astex Pharmaceuticals (ASTX) Q1 2013 Earnings Call April 29, 2013 4:30 PM ET
Operator
Good day, ladies and gentlemen, welcome to the Astex Pharmaceuticals Q1 2013 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Timothy Enns, Senior Vice President, Corporate Communications and Marketing. Please begin.
Timothy L. Enns - Senior Vice President of Investor Relations, Business Development & Corporate Communications
Thank you, operator. Good day, and thank you for joining us for Astex Pharmaceuticals 2013 First Quarter Financial Results Conference Call. With me today are Dr. James Manuso, Chairman and Chief Executive Officer; Dr. Harren Jhoti, President and Director; Dr. Mohammad Azab, Chief Medical Officer; Dr. Martin Buckland, Chief Business Officer; and Michael Molkentin, Chief Financial Officer.
In a few moments, our officer team will deliver remarks on the 2013 first quarter financial results and our business outlook for the year. After prepared comments, we will open the line for questions. Earlier today, we issued a press release with our financial results. A copy of the press release is available in the Investor Relations section of our website at www.astx.com. In addition, this call is being webcast and may be accessed via the Investor Relations section of our website. A webcast replay will be available for 30 days.
During this call, we will make projections and forward-looking statements that are based on management's current expectations. Actual results may differ materially from these forecasts and projections due to various factors. There are significant risks and uncertainty in biotechnology research and development. There can be no guarantee that our projects, products or product candidates will progress preclinically or clinically as we expect, or that we will ultimately obtain approvals for the indications that we seek. Moreover, even if our products or product candidates are approved in the future, we cannot guarantee they will be commercially successful.
The company's results may also be affected by a variety of factors, such as competitive developments, launches of new products, the timing of anticipated regulatory approvals or regulatory action, the actions of our strategic partners and collaborators with respect to the products we license or codevelop, and patent disputes and litigation.
For additional information and discussion concerning the risk factors that affect the company's business, please refer to the company's filings with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements.
In the coming weeks, we'll be participating in the following investor conferences. Tomorrow, April 30, in New York City, the Needham Healthcare Conference; in June, the Jefferies Healthcare Conference; and in July, the JMP Securities Healthcare Conference. Additionally, we will be holding our annual meeting of stockholders on June 13, at our headquarters in Dublin, California. Information on these events can be found in the Investor Relations section of our website. I'll now turn the call over to Dr. James Manuso, who'll provide highlights of our accomplishments during the 2013 first quarter. Jim?
James S. J. Manuso - Chairman and Chief Executive Officer
Thank you, Tim. Good afternoon and thank you for joining the Astex Pharmaceuticals 2013 First Quarter Conference Call. I'm very pleased to report that Astex has had a successful first quarter on multiple fronts. Patient accrual in our Phase II programs progressed very well. Preclinical data supporting our expanded clinical trial programs and our partners' clinical program data were received positively at the AACR Meeting.
On the revenue side, Dacogen royalty has continued to grow at a nice pace. In some, the first quarter's performance has been a great way to start a very exciting year for our company. Our progress has been appropriately recognized by Wall Street. During the first quarter, senior biotechnology analysts from 2 banks, JMP Securities and RBC, initiated new coverage on Astex. Our sell side coverage now consists of 3 bank analysts and one independent analyst. This additional interest and exposure has helped to raise our valuation to a point where larger growth-oriented funds can evaluate, follow and, potentially, benefit financially from our progress.
In the first quarter, Dacogen royalty revenues increased over 7% to $22.1 million compared to the same prior year period. And we reported net income of $488,000. Our cash and equivalents position remains strong. We ended the quarter with $137 million. Janssen, the Dacogen sub-licensee outside of North America, continues to register Dacogen for sales, marketing and reimbursement in the individual European Union countries and elsewhere for the treatment of patients aged 65 years and above, with newly diagnosed de novo, or secondary acute myeloid leukemia, or AML, who are not suitable for induction chemotherapy. The Dacogen European market is protected by a 10-year orphan drug designation that was granted at the time of the product's approval. Recall also that the AML population in the E.U. is 18,000 patients, 10,000 of whom are elderly.
It was not that long ago that no one knew what hypomethylators were, but last year, in 2012, global sales of the 2 marketed hypomethylators, Dacogen and Vidaza, exceeded $1.1 billion. Astex will continue to participate in this important worldwide market despite the anticipated expiration of Dacogen's orphan drug designation in the United States, next month. As a reminder, separate and apart from Dacogen's approval in elderly AML in the E.U., Janssen has obtain marketing approval for this important medicine in the myelodysplastic syndromes, or MDS, indication in over 35 countries. Astex will continue to receive escalating royalties at rates from 20% to 30% on all net sales of the drug worldwide, regardless of indication and irrespective of which of our partners, Eisai in North America or Janssen in the rest of the world, makes the sale.
In a few moments, I will turn the call over to our officers so they can update you on our important programs and initiatives. Our Chief Medical Officer, Dr. Mohammad Azab, will update you on our 2 prioritized clinical programs, SGI-110 and AT13387.
Our President, Dr. Harren Jhoti, will then discuss Astex's innovative epigenetics partnerships with Cancer Research Technology Ltd., or the CRT, and the Institute of Cancer Research, or the ICR, in London, and the discovery collaboration with CRT and Newcastle University.
Our Chief Business Officer, Dr. Martin Buckland, will provide an update on our partnered programs with major pharmaceutical companies, under which, 4 novel drugs are being tested in the clinic. Taken together, our partnered programs have the potential to generate for our company more than $800 million of milestone payments, plus eventual royalties on sales.
Lastly, before I make a few final comments, our Chief Financial Officer, Michael Molkentin, will review our 2013 first quarter financial results and outline our guidance for the remainder of the year.
Let's now begin with an update on our clinical programs by Dr. Mohammad Azab. Mohammad?
Mohammad Azab - Chief Medical Officer
Thank you, Jim. And good afternoon, everybody. The Astex 2 prioritized pipeline products, the SGI-110 and AT13387, continue to progress steadily in 6 clinical trials. As you know, SGI-110 is a low-volume subcutaneous, hypomethylating agent, and the Phase II dose expansion stage and the MDS and AML trial continues to accrue steadily. Following the presentation of the Phase I dose escalation data at the ASH meeting last December, we have reported clinical [ph] responses, differentiated sustained exposure to decitabine from SGI-110 and potent demethylation data, which was presented at the ASH meeting and demonstrated that SGI-110 can achieve responses in heavily pretreated MDS and AML patients, including those who are previously treated with Dacogen or Vidaza. SGI-110 has progressed into the dose expansion phase, which is structured in 4 patient cohorts and randomized to either the biologically effective dose or the maximum dose that was well tolerated in both MDS and AML patients using the daily times 5 regimen. These 4 patient cohorts are: the first line MDS patients, relapsed/refractory MDS, first line elderly AML patients not suitable for induction chemotherapy, and the relapsed/refractory AML patients.
There's also a fifth nonrandomized cohort of relapsed/refractory AML who are treated with a more intense regimen as studying the biological effective dose with the daily x 10 schedule. We're now over the 50% accrued in the Phase II dose expansion stage in the MDS and AML trial, and we are on track to complete overall patient accrual for this trial of approximately 200 patients and also report on the first cohort, which completed accrual of the relapsed/refractory AML patients by year end.
Also by year end, the Astex expects to select one or more disease indications to progress SGI-110 into the pivotal Phase III stage. Preclinical data was presented during several presentations at the American Association of Cancer Research meeting, or AACR. The data reconfirmed that potent demethylating activity of SGI-110 in different tumor models and supported the potential of SGI-110 in the treatment of platinum-resistant ovarian cancer, and also as an immune modulatory agent. Phase II studies in platinum-resistant ovarian cancer and hepatocellular cancer are both actively recruiting patients with initial data presentations expected in 2014.
Astex's other prioritized clinical program is the HSP90 inhibitor, AT13387. At AACR, there was preclinical data presented supporting the rationale for studying this agent in our randomized Phase II trial in castration-resistant prostate cancer patients. Preliminary data from both the prostate and the ALK-positive lung cancer trials of AT13387 should be available for scientific presentations next year. Both trials are examining the benefit of AT13387 both as a single agent and also in combination. The prostate trial combines AT13387 with abiraterone acetate, while in the ALK-positive lung cancer trial, the agent is combined with crizotinib. Achievement of safety of the combination and confirmation of the biological activity in terms of down-regulation of the target client proteins for HSP90 inhibition will guide the expansion into the randomized Phase II part for both the castration-resistant prostate cancer and the ALK-positive lung cancer trials.
I will now like to turn the call over to Dr. Harren Jhoti, who will provide an update on our discovery partnerships. Harren?
Harren Jhoti - Co-Founder, Chief Executive Officer and Director
Thank you, Mohammad. In the latter half of 2012, Astex initiated 2 new drug discovery collaborations with prestigious academic U.K. institutions. In the third quarter of last year, Astex began a partnership with Cancer Research Technology, or CRT, and the Institute of Cancer Research, or ICR, based in London, to discover and develop drug candidates against the multiple myeloma SET domain, or MMSET, an exciting new epigenetic target indicated in blood cancer.
A chromosome translocation of the MMSET gene is linked to disease etiology in multiple myeloma, resulting in overexpression of MMSET in patients. The basis of the collaboration is to combine Astex's world-renowned, fragment-based drug discovery platform, Pyramid, with ICR's expertise in blood cancer biology, as well as their proven success in drug discovery. This collaboration is proceeding well and builds upon a productive partnership from 2003, under which, 2 compounds, AZD5363 and AT13148, that target the key tumor cell survival pathway kinase, PKB/Akt, were discovered, and which have been advanced into clinical trials by AstraZeneca and Cancer Research U.K., respectively.
Astex also began a 5-year strategic drug discovery alliance late last year with CRT and the University of Newcastle. The partners will discover and develop new cancer drugs in collaboration with researchers at the Cancer Research U.K. Drug Discovery Program at the Northern Institute of Cancer Research, or NICR, based in Newcastle University. Within the collaboration, Astex will provide funding, annually, to the university to support research across biology, chemistry, pharmacology and imaging at the NICR, to identify and develop new cancer drugs and associated biomarkers. Astex has an exclusive option to license any of the drug candidates being developed in the NICR portfolio.
This partnership follows a prior collaboration between Astex, Newcastle and CRT, on Fibroblast Growth Factor Receptor, or FGFR, a key cancer target, which led to the discovery and development of the clinical candidate that was subsequently licensed to the Johnson & Johnson company, Janssen. JNJ42756493 is currently being progressed in Phase I clinical trials by Janssen.
I will now turn the call over to our Chief Business Officer, Dr. Martin Buckland, who will discuss our clinical stage partner programs, including LEE011, AZD5363 and JNJ493. Martin?
Martin Buckland - Chief Business Officer and Director
Thank you, Harren. Harren has described some of the new collaborations which use Astex's Pyramid fragment-based drug discovery platform. Astex's historic partnerships with academic centers of excellence, such as the ICR and the NICR, and with large pharmaceutical companies, have already produced an exciting portfolio of novel drugs, including 5 that are now being tested in the clinic.
At the recent AACR meeting, in a late breaking oral symposium, our partner, AstraZeneca, discussed results of 2 Phase I multi-center trials of AZD5363, an inhibitor of a key enzyme in the mTOR/PI3K/AKT tumor cell survival pathway, in which safety, tolerability, preliminary efficacy and biomarker data in patients with advanced solid tumors was presented. Partial responses were observed in 2 patients with mutations in the PI3K/AKT signaling pathway. AZD5363, an orally bioavailable, selective and potent pan-AKT inhibitor is currently being tested in 4 Phase I clinical studies, including estrogen-receptor positive breast cancer and in prostate cancer. The AKT pathway is an important mechanism by which tumor cells evade killing by many commonly used anticancer agents.
Additionally at AACR, our partner, Novartis, presented data on LEE011, an orally active selective inhibitor of 2 key cell cycle kinases, CDK4 and CDK6, showing potent activity in a definable subset of human neuroblastoma cells lines. LEE011 is currently being evaluated in 5 Phase I and Phase I/II studies, including in combination with a number of Novartis priority pipeline drugs. Most recently, the FDA granted breakthrough designation status to another CDK4, CDK6 inhibitor, now advancing in the clinic.
In a different therapeutic area, AstraZeneca has advanced AZD3293, a beta-secretase inhibitor in 2 Phase I studies. A single ascending dose study in volunteers and an ascending multiple dose study in volunteers and Alzheimer's patients. Beta-secretase, also called BACE 1, or beta-site of amyloid precursor protein enzyme, is an aspartic acid protease important in the formation of myelin sheets in peripheral nerve cells and is implicated in the pathogenesis of Alzheimer's disease. Inhibitors which brought the action of this enzyme could help to prevent the buildup of beta amyloid, which may help slow the progression of, or stop the disease.
In partnership with Janssen, JNJ42756493, or 493, an orally active selective inhibitor of Fibroblast Growth Factor Receptor, or FGFR, is being tested in a Phase I study in advanced refractory cancer or lymphoma patients. 493 was discovered as part of a successful collaboration between the University of Newcastle and Astex, and formed part of the oncology partnership entered into between Astex and Janssen in 2008. Astex stands to earn further milestones and royalties on product sales as all these product progress through the clinic and into the market.
Finally, AT13148, an orally bioavailable inhibitor of AGC kinases, including PKB/Akt, PKA, ROCK and p70S6 kinase, was discovered as part of an academic partnership with ICR and Astex. AT13148 is currently being tested in a Phase I clinical study being conducted by Cancer Research U.K. as part of their clinical development partnerships program. New data on the compound was also presented at the recent AACR meeting. AT13148 is wholly owned by Astex.
In regards to our discovery partnership with GlaxoSmithKline, or GSK, Astex continues to make good progress with GBP 9.2 million in research-based milestones earned to date since the start of the collaboration. This partnership applies Astex's Pyramid platform to targets of interest to GSK in multiple therapeutic areas.
At this time, I'll turn the call over to our Chief Financial Officer, Michael Molkentin. Michael will provide details on our 2013 first quarter financial results. Michael?
Michael Molkentin - Chief Financial Officer, Principal Accounting Officer and Corporate Secretary
/
Thank you, Martin. I will now comment on our 2013 first quarter financial results. Total revenues for the 2013 first quarter were $22.1 million compared with $22 million for the same prior year period. Total revenues for the 2013 first quarter consist entirely of royalty revenue of $22.1 million, compared with royalty revenue of $20.6 million for the same prior year period.
Total operating expenses for the 2013 first quarter were $23.9 million, compared with $20.6 million for the same prior year period. The primary reasons for the increase in total operating expenses for the current year quarter, when compared with the same prior year quarter, are increased research and development cost associated with SGI-110 and AT13387 and an increase in stock-based compensation expense, offset, in part, by lower amortization of intangibles cost and a reduction in general and administrative expenses.
The noncash amortization of intangibles was $1.9 million for the 2013 first quarter, compared with $2.2 million for the same prior year period, while stock-based compensation expense, also a noncash expense, was $1 million for the 2013 first quarter, compared with $765,000 for the same prior year period.
Net income for the 2013 first quarter was $488,000, or $0.01 per basic and diluted share, compared with net income of $4.2 million or $0.05 per basic and $0.04 per diluted share for the same prior year period. Included in the 2013 first quarter net income, is a foreign currency translation loss of $1.3 million, compared to $4,000 for the same prior year period. Also included in net income, is an income tax benefit of $3.8 million, compared with a tax benefit of $2.8 million for the same prior year period. The income tax benefit for the current and prior year first quarter is primarily due to the recognition of tax benefits associated with the amortization of deferred tax liabilities resulting from the acquisition and utilization of a foreign research and development tax credit related to our U.K. subsidiary.
We continue to report a strong financial position. As of March 31, 2013, the company had approximately $137 million in unrestricted cash, cash equivalents and current and non-current marketable securities, compared to approximately $138 million at December 31, 2012.
Reflected in today's news release is the company's financial guidance for 2013, which remains unchanged from our prior guidance. Selected comments on our financial guidance include forecasted annual royalty revenue for 2013 remains unchanged at $55 million for the year. Though we anticipate the potential of earning additional development and license revenue from our partnered programs during 2013, we do not guide to such revenue due to the general uncertainty around, and timing of, milestone achievements and payments.
We continue to forecast that research and development expenses will increase from $60 million, in 2012, to approximately $67 million for 2013. The increase from the prior year reflects the continuing ramp up of the multiple Phase II clinical trials related to our SGI-110 and AT13387 development programs.
The noncash charge for the amortization of intangible assets is anticipated to be approximately $8 million for 2013, while general and administrative expenses are expected to decrease modestly from the prior year to $15 million, and the estimated income tax benefit continues to be forecasted at approximately $5 million for the year.
Considering the impact of the operational initiatives influencing our financial guidance, the forecasted net loss of approximately $30 million for 2013 remains unchanged, but keep in mind that the forecasted net loss does not reflect any anticipated development and license revenue that may result during this period.
Now on cash operating charges for 2013, included in total operating expenses, continue to be estimated at approximately $12 million for the year. This concludes the review of our 2013 first quarter financial results and comments on our annual financial guidance for 2013. I will now turn the call back to Dr. Manuso for closing remarks.
James S. J. Manuso - Chairman and Chief Executive Officer
Thanks very much, Michael. Astex started 2013 with encouraging SGI-110 Phase I data as reported at the ASH meeting. Interest in the SGI-110 data and the Phase II clinical program designs continue to grow. New data from the Phase I trial will be presented at the European Hematology Association meeting this June.
In terms of our revenue base, Dacogen product sales continue to do well in North America and are showing steady progress in the E.U. Financially, we have maintained considerable strength with cash and equivalents of $137 million at our disposal as of the end of the first quarter. Within R&D, our partner discovery programs have successful track records of producing viable, clinical candidates. Our partner funded product pipeline now boasts 5 drugs in Phase I or Phase I/II trials. Our internal prioritized clinical programs are designed to be properly powered to provide clear proof-of-concept data and direct the design of potential Phase III trials.
By year end, we anticipate selection of one or more SGI-110 disease indications for our Phase III clinical trials consistent with our commercialization strategy. We continue to be on track to file one new IND by year and. Finally, remember that Astex owns fully its prioritized medicines and development and virtually all of the others in its portfolio. These ownership positions are supported by more than 300 issued patents and more than 560 pending applications. The Astex's management team and I look forward to updating you on our progress in the months ahead. Dr. Harren Jhoti, Dr. Mohammad Azab, Dr. Martin Buckland, Michael Molketin, Tim Enns and I, are now ready to answer your questions. Operator, we're pleased to take questions at this time.
Question-and-Answer Session
Operator
[Operator Instructions] The first question is from Michael Yee of RBC Capital Markets.
Michael J. Yee - RBC Capital Markets, LLC, Research Division
Question for Mohammad and the team. You said a goal was to pick a pivotal spill [ph]indication by the end of the year. I guess my question is, how can you do that if you don't get all the data from all these different cohorts until 2014? Are you observing activity or observing the ongoing study throughout the year? Is that basically what's going to guide your decision, you're basically looking at the results as you go through the year? And then I have a follow-up.
James S. J. Manuso - Chairman and Chief Executive Officer
Well, Michael, as you know, these are open labeled trials, so although we will have the complete, probably, reasonably mature data from one cohort, which is the relapsed/refractory AML patients, we will have emerging data from the other cohorts because we said we'll hold the whole trial, with complete enrollment, before the end of the year and, hopefully, that would be 2 months before the end of the year. So for -- in that perspective, we will have seen, at least, some early data from the other cohorts as well. Remember the data mainly also is driving the choice of the schedule, because we're testing 2 different schedules, 60 and 90, with a 5-day, and also, there is a third schedule, with a 10-day regimen, which is a more intense regimen, only for the relapsed/refractory AML patients, which is also recruiting well. So hopefully, with the complete data from the relapsed/refractory AML and, at least from the fully enrolled trials, but not the fully mature data from the other cohorts, we'll be able to make the determination about the indication and the schedule. Having said that, the data is not the only driver for the indication as well. As you know, there is other factors in driving the indication which, such as the commercial assessment, the feasibility of the trial, the probability of success, the unmet need and all of that, are being taken into account. And those -- that information is already available to us. Basically we know what are the indications that are most feasible and have the highest unmet need, and that would be and kind of I think I've said that before, certainly, the patients who are in the relapsed/refractory setting or the second line setting, are the patients who are -- reasonably have the highest unmet need in terms of Phase III potential indication.
Michael J. Yee - RBC Capital Markets, LLC, Research Division
Okay. And then a follow-up then is, you're seeing -- you've seen prior response to, obviously, in Phase I and you're going to be looking at this across your Phase II indications. When you look across the landscape, in your experience, how much does response rate correlate with survival, in both relapsed/refractory AML and MDS in frontline settings? You guys obviously spent a lot of years looking at all this and have worked on these drugs. So what can you say that help gives confidence that response rates we're going to see is going to be driving survival?
James S. J. Manuso - Chairman and Chief Executive Officer
Well, I mean -- it certainly is not only response rate, I have to say that, we would also would like to look at the duration of response which is the quality of those responses. The literature has been mixed on the first -- I mean, I can already exclude the second line MDS. There is very little literature, almost none, on second line MDS. And I think that indication should correlate well with survival, even with stable disease only, because -- or hematological improvement, the reason for that, I say that, is that, basically, after failure of Dacogen and Vidaza, there is no other treatment that is being used. There's not even a treatment that is effective, or had been reported to be effective, in second line setting, even as an off-label use. So I think we're pretty confident that if we're seeing any stabilization of the disease and hematological improvement in the second line setting that would be a good indication and, hopefully, would translate into survival, since these patients, on average, the median survival in the second line MDS, after failure, is just about 5 months, so very short. So that's kind of -- on the second line setting for MDS. For relapse AML also, the data are not really that strong in terms of whether there is a correlation or not with response rate. As you know, some of the data from the front line setting, when you look at the frontline data and kind of indications which try to combine with a 7 plus 3, or adding to the 7 plus 3, there has not been a correlation between a high response rate and survival. As you know, for the elderly AML patients, it has been even more controversial since some of the early trials in elderly AML show that, with lower intensity regimen, you get lower response rate, but you have similar survival to more intensive regimen for the elderly patients. The best data actually coming from the front line setting of AML is the Dacogen data, Phase III data. As you have seen in the Dacogen -- Daco16 trial, which was the basis for approval in Europe, Dacogen doubled the response rate from about 8% to 16%, and also showed a 50% improvement in survival. So at least from that trial, which is a large, 485 patient trial, you can see that there was a correlation, apparent correlation, between response rate and survival. And that response rate was not that high. Like as we said, response rate was only 16% but that basically translated into a 50% improvement of survival.
Operator
The next question is from Mike King of JMP Securities.
Michael G. King - JMP Securities LLC, Research Division
Maybe just a follow up on Michael Yee's questions regarding user correlates of outcome. Mohammad, I just want your thoughts a bit on whether the LINE-1 biomarker is a possible guide to better outcome or is that still too nascent to really give us a clear view to outcome?
Mohammad Azab - Chief Medical Officer
I think that's a very interesting point, Mike. It is true that we have, not in the -- like in the past, and I was just being -- there was an acute leukemia forum here in San Francisco a couple of weeks ago, and key opinion leaders still talk about the fact that LINE-1 demethylation did not really correlate with responses of survival in the MDS population. And that statement is true, even in our hands, with the Phase I data that we presented at ASH. Having said that, there is very little research that I know of that correlated LINE-1 with activity in AML. And as you know, from our data that was presented at ASH, we have seen, at least from the preliminary Phase I data, a very nice and strong correlation between LINE-1 demethylation and responses in AML. Whether that is enough to consider using LINE-1 as a patient selection strategy, that -- I think that's still to be confirmed by the Phase II expansion data.
Michael G. King - JMP Securities LLC, Research Division
Okay. All right, fair enough. And then just to turn to the AML studies, again, more for point of clarity. With regard to the more intense regimen, I'm just wondering if you -- would that help you understand what regimen you'll take into registration directed studies? In other words, are you deciding on 5 days for 1 population, 10 days for another? Or if 10 days seems to be superior in the relapse/refractory, you would do 10 days for sort of first line?
Mohammad Azab - Chief Medical Officer
As you know, the Phase II expansion is 4 different patient cohorts. For 3 of those cohorts, the 10-day regimen is not available, so it would always be a 5-day regimen, and the choice will be between the 60 milligram per meter square, which is the biological effective dose, or the higher dose, which is 90, so that's for the 3 patient cohort. The only exception is the fourth cohort, which is the relapse/refractory AML. And so the answer is, yes, for that. If we choose that indication, it's certainly one of the high-priority indications for us because of the high unmet medical need. In the relapsed/refractory AML, we have to make the determination, not just between 60 and 95 days, but also between those 2 regimens and the 10-day intense regimen. So we'll have to wait also for that data to make that determination.
Michael G. King - JMP Securities LLC, Research Division
Okay. And then one set of studies that was, I guess, conspicuous by its absence, or by their absence, was any immune priming studies. There was a fair bit of discussion at AACR regarding the sensitivity to immunotherapies, like PD-1 antibody intervention, subsequent to HMA treatment, so I just wondered if that's on your radar screen and what you might be able to comment about it?
Michael Molkentin - Chief Financial Officer, Principal Accounting Officer and Corporate Secretary
Yes, Mike. That's a good question. We certainly have some plans for immunomodulatory clinical trials. Those plans have not been finalized yet. And these -- the activity to start those kinds of trials have not started yet, that's why we're not commenting on it now. But rest assured, once we start planning and have clear idea about that type of study and also the timeline for that study, we'll be communicating that to you.
Michael G. King - JMP Securities LLC, Research Division
Right, okay. And then if I could, just real quick, turn to Michael Molkentin. I just wanted to say, on the financials, can we just simply take your current cash balance and the net loss, I guess, less amortization of intangibles and just do the subtraction for year end cash?
Michael Molkentin - Chief Financial Officer, Principal Accounting Officer and Corporate Secretary
Yes, that's an oversimplification. I would kind of position it just slightly differently. We're guiding to a $30 million loss and we have, in operating expenses, about $12 million of noncash items, which nets us about $18 million. Now that number can be modified or influenced by any potential development and license revenue that we receive this year, and any payments that we may make on our long-term, or not on our long-term, but on our deferred consideration that we have still outstanding. So yes, to how you described it, but I -- giving you a few more things to think about, but you should probably come within about the same range.
Operator
The next question is from Jason Zhang of Edison Group.
Jason Zhang - Edison Investment Research Limited
Thanks for the update on the pipeline, that was very helpful. But could you also mention the other programs that you have? For example, 283, amuvatinib and are they -- are you still actively conducting trials? Are you have done all the study necessary and you are just waiting for more of a decent decision on those pipelined drugs? And also your own CDK inhibitor 119.
James S. J. Manuso - Chairman and Chief Executive Officer
This is Jim Manuso. First, just let me say that those programs are fully in the hands of our partners. They continue to advance clinically. We intend, of course, to give updates as we receive those. And I think Martin Buckland is in a good position to recite the status on a program-by-program basis. So Martin, would you be so good?
Martin Buckland - Chief Business Officer and Director
Sure, Tim. I think, Jason, to be fair, was actually asking about AT9283, about amuvatinib, and also about AT7519, so it may be better for Mohammad to respond on those 3 programs. I can certainly pick up on the other partner programs.
Mohammad Azab - Chief Medical Officer
Yes, for that, we have not -- Jason, this is Mohammad, we have not kind of updated any new information on the 9283, which is an Aurora/JAK kinase inhibitor and the 7519 program, which is the Pan-CDK inhibitor, because these programs we have not started any new trials. And most of the trials that are currently are ongoing are either have been reported or have already fully reported. So the only activity going on with 9283 is studies by Cancer Research U.K. in pediatrics, in solid tumors and pediatrics, leukemia. And the solid tumor trial had enrolled, the leukemia trial is still enrolling. For the 7519, and the only Astex-sponsored study which had complete enrollment is a multiple myeloma study, and we had not reported on that yet. The other 2 trials are not sponsored by Astex, they are sponsored by NCI Canada. This is a chronic lymphatic leukemia trial and a mantle cell lymphoma trial that is currently enrolling with NCI Canada. So that's why the reason, as you know, we are not starting any new trials with these programs. Certainly, once we have completed the trials and we have data from these trials, will be communicated in scientific presentations, and we will update you on that. The only other drug that you haven't mentioned, but I think Martin alluded to, is amuvatinib, or MP470. This is the DNA damage repair inhibitor. We have completed the small cell lung cancer trial, as you know, late last year, and we have reported that we are not progressing this trial further because we have not seen the level of clinical activity that we had basically put the primary endpoint at, although that we have seen responses in that trial, the clinical data from that trial has been presented at the AACR meeting, which reviewed the 23 patients that were enrolled in that trial. So that really completes all the other Astex programs that have not been covered here in the call.
Jason Zhang - Edison Investment Research Limited
And also a question on Dacogen. I guess, Q1 is -- from the revenue -- royalty revenue reported, looks like it's a very similar to Q1 last year. Does that mean the AML indication from Europe really hasn't really have any meaningful contribution to the revenue?
James S. J. Manuso - Chairman and Chief Executive Officer
I'll comment on that. As you know, at this point, the drug is being gradually approved in the G5 and other E.U. countries. We anticipate the ramp up will be meaningful, but we can't really assess that until we've been in the market long enough in order to get some real clarity on that. What we can say and remind people is that our partner's Janssen, very rapidly registered the drug and began selling, marketing and getting it reimbursed in the -- a couple of the G5 countries. And pricing, we don't have great clarity on that as of yet. You know that has to be negotiated in a country-by-country basis, but we certainly believe that the anticipated ramp is going to be meaningful. We don't know when the curves will cross, so to speak, and that's something that we're monitoring very closely. But it certainly is something that we anticipate to fall off as far as royalty revenues are concerned in the U.S. as generics begin to come in next month. So that's something that we'll be updating you on, on an ongoing basis as we learn more.
Jason Zhang - Edison Investment Research Limited
Okay. Just on that subject, you said that generics will come next month. Have we seen a Paragraph IV for filed yet in the U.S.?
James S. J. Manuso - Chairman and Chief Executive Officer
No, it doesn't apply in this instance.
Operator
The next question is from Boris Peaker of Oppenheimer.
Boris Peaker - Rodman & Renshaw, LLC, Research Division
Most of the clinical questions were answered, I just want to know a little clarification on the prior caller's question, specifically, regarding Dacogen royalties. I think, Jim, you just mentioned that the entry of generics is not required for the partner to stop paying royalties. It sounds like it's only when the patent or the orphan exclusivity runs out. Could you just confirm that? And does the same hold in all other geographies? Or are sub-geographies triggered by the entry of a generic?
James S. J. Manuso - Chairman and Chief Executive Officer
Yes and yes. The primary issue here is the rapidity and the number of generics coming in. And we just don't have clarity on that at this point. We certainly believe that it's a meaningful market. And we just don't know at this point, who and how many. Tim?
Timothy L. Enns - Senior Vice President of Investor Relations, Business Development & Corporate Communications
Boris, let me give you clarity on that, and you are correct in the way you'd assess it. In every geography, it is a 20-year license that starts from the date of first approval, then in whatever that geography you have your exclusivity period, but the license is for a full 20-year period. What you're referring to is a very common license structure, where there's a patent involved, and when the patent is invalidated or expires, and as soon as the generic entrant come in, then the requirement to pay goes away. That situation does not occur with any of our licenses or regarding Dacogen is that in all of them, we've given you an example, if a new territory were to be brought on board, such as Japan, for AML or something like that. Then the same royalty rate would apply, the same 20-year line, would apply and then whatever Orphan Drug protection would be, would be the exclusivity period.
James S. J. Manuso - Chairman and Chief Executive Officer
Yes, Boris, it's a 20-year payment schedule in each jurisdiction on a jurisdiction-by-jurisdiction basis. So if it gets approved in Japan, say, 5 years from now, that takes us out 25 years. Regardless of generics, regardless of any competitors or anything else.
Operator
The next question is from Michael Yee of RBC Capital Markets.
Michael J. Yee - RBC Capital Markets, LLC, Research Division
Just a follow up on ASCO, do you expect that any of the data in the abstract would be different? Or it's exactly the same that was submitted from ASH? And then when we get to ASCO, obviously, you have durability data from that study as some of those patients have obviously passed away since then. In your clinical experience, what is -- what should investor expectations be for good durability? I mean, obviously, these patients are really, really sick. So a couple of months of durability is good for a response? Help us understand that.
James S. J. Manuso - Chairman and Chief Executive Officer
Mohammad?
Mohammad Azab - Chief Medical Officer
Michael, I think -- we do not have any data actually at ASCO. We can -- alluded to that, in one of the press releases regarding that, essentially, as you know, the deadline for submission of ASCO is the 1st of February, which is basically just a few weeks, 6 to 7 weeks from the ASH presentation that we had all of the data presented. So at the time of submission of the abstract, there was not really enough data for that abstract to be considered for the presentation. So we're not presenting at ASCO. We've chosen to follow up on that durability data with both of the European meetings that we have targeted for the year. So we have submitted abstracts for both European Hematology Association, which is coming up in June, and also for the ESMO ECCO, or the European Cancer Congress, which is coming up in late September. Both are European meetings and we have not had exposure in Europe before. As Jim alluded to in the call, we have already our abstract accepted for presentation at the European Hematology Association, which is this year, in June 13 to 16, in Stockholm. That abstract has durability of responses in the MDS population. For the AML population, we have abstract that actually describes some new biomarker data that we have generated from the Phase I and also the durability of responses in the AML population. That abstract was submitted to ESMO. Usually, according to the ESMO ECCO website, we will know around July, if that abstract was selected for presentation or not, then we'll communicate that.
Michael J. Yee - RBC Capital Markets, LLC, Research Division
Okay, and then last question in is on the ongoing relapsed/refractory study. In Phase I, it was fairly sick population, 3 median lines of therapy. In the ongoing study, is there some sort of different entry criteria? Do you expect these types of patients or do you know the types of patients, obviously, since the study completed enrollment in relapsed/refractory AML? Median lines of therapy, are they a little bit more healthy?.
Mohammad Azab - Chief Medical Officer
They are still heavily pretreated patients in AML. We wanted them really to reflect our potential Phase III indication. Our view of the Phase III indication is that we will take relapses regardless of the number of prior regimens, unlike some of the other drugs in development in relapsed AML, where they usually kind of focus either on the first relapse or subsequent relapse. We have taken patients with many prior regimens. The only difference is that, for the AML patients, for second line MDS patients, all of them have received Dacogen or Vidaza, while for the relapsed/refractory AML patients in the Phase II expansion, we are not requiring that they have received Dacogen or Vidaza before. But they could have received a number of prior regimens. So they're not really healthier than the Phase 1 population, but we specifically wanted to do that to be reflective of our potential Phase III design. That's why as I said, the most important thing for these patients is we have enough durability of responses in order to be able to forecast an improvement in survival. As you know from some of the relapsed large Phase III trials that have been conducted by other drugs that are currently in development, a recent one that have just been reported a few weeks ago with LSI therapy. The median survival of the drug treatment versus the control arm were 3 to 3.5 months. So the median survival is very short, so hopefully, any impact in terms of durable responses could positively influence such a short survival. And that's really our target population.
Operator
The next question is from Mike King of JMP Securities.
Michael G. King - JMP Securities LLC, Research Division
I'm just wondering Mohammad, Harren, if you could talk about any biomarker development that you're using in conjunction with the 13387?
Mohammad Azab - Chief Medical Officer
So for 13387, what we're looking at, it's not going to be -- we don't expect there'll be any predictive biomarkers, Mike, because, as you know, this is a chaperone protein that affects many other client proteins. The main biological endpoints that we're looking at in the Part A of these trials is confirmation in human tumors that we are actually down-regulating the client protein, and thus, providing what I call a biological proof of principle, in that the drug is doing what it's supposed to do in terms of down-regulation of the client protein. We are doing this by collecting tumor material, before treatment and after treatment, and using extensively a technology of circulating tumor cells, which is established for prostate cancer and we're working with another company that had an established CTC detection for lung cancer, and both methods had shown the ability to measure the down regulation of the androgen receptors, in case of prostate cancer, and of the ALK-translocated protein, in case of the lung cancer, and we want to see those first before proceeding to the larger, more expensive Phase II part of the trial. Because, frankly, if we don't see a convincing evidence that we are down-regulating the client protein, then the whole biological principle of the HSP90 inhibition is going to fall short and that's something, as kind of I said to -- many times during corporate presentations and during one-on-one meetings, it is something that's really lacking in the HSP90 inhibitor's development. If you look at all the clinical data generated in the past decade, with all these HSP90 inhibitors, there is not a single one that showed convincing evidence of down-regulation of the client protein in human tumors in patients. We have, of course, tremendous evidence and beautiful down-regulation of client proteins in animal models. But we don't, unfortunately, we don't have that evidence from clinical data yet. And we are struggling hard to get that evidence from our trials before we proceed to the Phase II and, hopefully, Phase III part.
Operator
I would now like to turn the call back over to Dr. Manuso for closing remarks.
James S. J. Manuso - Chairman and Chief Executive Officer
Well, thank you very much for listening in. We look forward to updating you on a realtime, ongoing basis and please don't hesitate, if you have any questions, to contact us. Thank you, again, for your time and attention and have a good afternoon.
Operator
Ladies and gentlemen, this concludes today's program. You may now disconnect. Good day.
6:01AM Astex Pharma provides SGI-110 update; oral presentation at AACR supports potential of SGI-110 in the treatment of platinum-resistant ovarian cancer (ASTX) 5.87 : Co announced that SGI-110 was featured in an oral presentation on Apr 9 at the American Association of Cancer Research (AACR). Researchers presented data from preclinical models supporting the ovarian cancer epigenetic chemosensitization effect of SGI-110. In established ovarian cancer xenograft models, SGI-110 in combination with platinum significantly delayed tumor growth compared to platinum alone. The researchers also showed that SGI-110 induced demethylation and increased expression of several tumor suppressor and tumor differentiation genes. In addition, SGI-110 slowed the repair of platinum DNA damage. These data support the ongoing clinical randomized phase 2 study in which SGI-110 in combination with carboplatin is being studied in platinum-resistant ovarian cancer patients.
he co also announced that the ongoing clinical phase 2 expansion study (Part B of Study SGI-110-01) in patients with myelodysplastic syndromes and acute myeloid leukemia has been expanded to ~ 200 patients by including an additional cohort of relapsed/refractory MDS patients to the ongoing three other cohorts. The phase 2 expansion trial has already enrolled more than half of the patients needed to complete the study. The trial is still on track to submit data from the relapsed/refractory AML cohort in the phase 2 expansion study to the ASH meeting for presentation in Dec this year.
Don't worry, it will be down.
Hmmm seems to still be going up. Sure you're not looking at your charts upside down? Just kidding............
Sell on the news, Buy on the rumer. This rull is good for this stock because PPS have no earninbg support!!!
.
Anural report said: As a result of our substantial research and development expenditures and minimal product revenues, we have incurred cumulative losses of $326.5 million through December 31, 2012, and have not consistently generated enough funds through our operations to support our business. Although we were profitable in the last three years, we expect to have operating losses over the next few years and we may never achieve sustained profitability.
2013 company expect lose 30mm or 0.32 a shares. once 1Q earning report coming out, PPS could be down. Less
After hour: a big sell 17,200 shares on bid $5.1287 for $88,214. He know something we don't know.
WWW.Stockcharts.com shows trend reverse to down. News already price in PPS on 4/3. Now going down.
what chart setups are you using to determine overall trends for stocks. Just wondering, i appreciate in advance. thankyou
I never buy at top to avoid to under the water.
Better buy your shares now! I agree on the profit taking,
but this beast is heading to $8.00
Been very bullish last several weeks.
Tomorrow we will see more down. How low you never know.
Astex Pharmaceuticals Pipeline Data Presentations at AACR
Press Release: Astex Pharmaceuticals, Inc. – 5 hours ago
DUBLIN, Calif., April 3, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the acceptance of thirteen abstracts covering internal and partner funded pipeline product data for poster or oral presentation at the American Association for Cancer Research (AACR) Annual Meeting April 6 to 10, 2013 in Washington, DC.
"AACR will be a foundational meeting for presenting significant data supporting our clinical programs," said James S.J. Manuso, PhD, chairman and chief executive officer. "Additional data presentations are anticipated for future meetings. Preliminary SGI-110 phase 2 data are expected to be presented at ASH."
SGI-110, a novel hypomethylating agent, will be highlighted in six presentations, including an oral mini-symposia presentation on ovarian cancer chemosensitization, as well as poster presentations on its immunomodulatory activity and its activity in lung cancer:
In vivo Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent, in Hematologic Malignancies
Abstract 680, Sunday Apr 7, 1:00 - 5:00 pm ET, poster presentation
SGI-110 and Entinostat Therapy Reduces Lung Tumor Burden and Reprograms the Epigenome
Abstract 679, Sunday, Apr 7, 1:00 -- 5:00 pm ET, poster presentation
The Novel, Small Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Abstract 4623, Tuesday, Apr 9, 4:05 - 4:20 pm ET, oral presentation
AT13387, an HSP90 inhibitor, will be presented in a poster session reporting preclinical data in sensitive and resistant prostate cancer tumor models:
In vitro and In vivo Anti-Tumor Activity of the Next Generation HSP90 Inhibitor, AT13387, in Both Hormone-Sensitive and Castration-Resistant Prostate Cancer Models
Abstract 2433, Tuesday, Apr 9, 8:00 am - 12:00 pm ET, poster presentation
Two of the four partner funded programs in our portfolio will have data supporting ongoing clinical development:
AZD5363, a PKB/Akt inhibitor:
Results of Two Phase I Multicenter Trials of AZD5363, an Inhibitor of AKT1, 2 and 3: Biomarker and Early Clinical Evaluation in Western and Japanese Patients with Advanced Solid Tumors
Abstract LB-66, Sunday, Apr 7, 3:30 - 3:50 pm ET, oral presentation
LEE011, a CDK4/6 inhibitor:
CDK4/CDK6 Inhibition is Potently Active in a Definable Subset of Human Neuroblastomas
Abstract 2744, Tuesday, Apr 9, 8:00 am - 12:00 pm ET, poster presentation
Additional poster references may be found on the AACR 2013 Annual Meeting website, and select posters will be made available for viewing on the company's website www.astx.com following the respective presentations.
http://finance.yahoo.com/news/astex-pharmaceuticals-pipeline-data-presentations-100000087.html
Heading to $8.00 > Initiated at Outperform by RBC.
Trade sees Astex on solid ground
By David Russell (david.russell@optionmonster.com) | optionMONSTER – 25 minutes ago
Astex Pharmaceuticals broke a key resistance level last earlier this month, and traders think there is no going back.
optionMONSTER's monitoring systems detected the sale of 5,000 July 3.50 puts for $0.38. Previous open interest was just 4 contracts, indicating that a new position was initiated.
The investor is now on the hook to buy shares of the drug developer for $3.50 if they fall to that level by expiration. But if it remains above it, he or she will keep the premium collected and the puts sold short will expire worthless. The strategy is commonly used when traders like a stock but don't want to expend capital upfront getting long. See our Education Section for more ideas on how you can turn time into money with options.
ASTX rose 1.35 percent to $4.13 in morning trading, and is up 38 percent in the last month. Most of that gain came after the company reported fourth-quarter earnings of $0.05 a share on Feb. 25, crushing the expectations of analysts who expected breakeven results. The move brought the stock back to levels last seen in late 2007, and triggered bullish alerts on stockMONSTER's researchLAB analytics tool.
http://investor.astx.com/releases.cfm
ASTX Video Chart 3/25/2013
http://www.missionir.com/videos.html
Astex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that Mohammad Azab, MD, chief medical officer, and Michael Molkentin, chief financial officer, will present at the 2013 RBC Capital Markets Healthcare Conference on Wednesday, February 27th in New York City.
The Company's presentation will begin at 8:00 a.m. ET. A live webcast of the presentation will be available in the Investor Events section of the Company's website, www.astx.com. The webcast will be archived for 30 days.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273
CONTACT: Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications & Marketing
Tel: +1 (925) 560-2810
E-mail: tim.enns@astx.com
Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Investor Relations
Tel: +1 (925) 560-2845
E-mail: susanna.chau@astx.com
Alan Roemer
The Trout Group
Managing Director
Tel: +1 (646) 378-2945
E-mail: aroemer@troutgroup.com
Pipeline Astex Pharmaceuticals™ has established a strong pipeline of small molecule, molecularly targeted drugs. SGI-110 and AT13387 are prioritized and advancing in multiple, potential indications.Program / Mechanism / IndicationPhase 1Phase 2Phase 3MarketedPartner
DACOGEN® – Hypomethylator (MDS)
DACOGEN® – Hypomethylator (Elderly AML)
AT13387 – HSP90 inhibitor (GIST, Prostate & Lung)
SGI110 – DNMT inhibitor (MDS, AML, Ovarian & Liver)
Amuvatinib/MP470 (SCLC)
AT7519 – CDK inhibitor (MM)
*
AT9283 – JAK/Aurora inhibitor (MM)
AT13148 – AGC kinase inhibitor
* Optioned.Partnered Products and ProgramsCompound Name / MechanismDiscoveryPreclinicalPhase 1Phase 2Partner
LEE011 – CDK4 inhibitor (Oncology)
AZD5363 – PKB/Akt inhibitor (Oncology)
JNJ42756493 - FGFr inhibitor (Oncology)
AZD3293 – BACE inhibitor (Alzheimer’s)
Multiple discovery milestones achieved
Multiple targets (Multiple therapeutic areas)
Discovery Obligations Completed
Partner targets (Oncology)
Astex Pharmaceuticals to Present at BIO CEO & Investor Conference
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that James S.J. Manuso, PhD, chairman and chief executive officer, will present at the 15th Annual BIO CEO & Investor Conference on Tuesday, February 12th in New York City.
The Company's presentation will begin at 11:30 a.m. ET. A live webcast of the presentation will be available in the Investor Events section of the Company's website, www.astx.com. The webcast will be archived for 30 days.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.
The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273
CONTACT: Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications & Marketing
Tel: +1 (925) 560-2810
E-mail: tim.enns@astx.com
Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Investor Relations
Tel: +1 (925) 560-2845
E-mail: susanna.chau@astx.com
Alan Roemer
The Trout Group
Managing Director
Tel: +1 (646) 378-2945
E-mail: aroemer@troutgroup.com
6:09AM On The Wires (WIRES) :Astex Pharmaceuticals (ASTX) announced that collaborators Cancer Research UK and its commercial arm Cancer Research Technology are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The 'master-switch' experimental drug, owned by Astex Pharmaceuticals, is being studied in a range of cancer types.
12:12PM Astex Pharma announces 'encouraging' results from dose escalation part of SGI-110 Phase 1/2 MDS and AML study in an oral rresentation at ASH (ASTX) 2.71 +0.01 : Co announced encouraging Phase I clinical results during a presentation at the American Society of Hematology (ASH) of SGI-110, a novel second generation hypomethylation agent. Data from the completed SGI-110 dose escalation part of a randomized Phase 1/2 first-in-human clinical trial, in patients with relapsed/refractory intermediate or high-risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) demonstrated a differentiated pharmacokinetic (PK) profile resulting in an extended half-life and exposure to decitabine as delivered by subcutaneous SGI-110. Excellent hypomethylation was achieved with higher doses in the daily regimen up to the Biologically Effective Dose (BED). BED was reached before the Maximum Tolerated Dose (MTD). Of the 17 heavily pretreated relapsed/refractory AML patients who were given therapeutic doses of SGI-110 and achieved adequate hypomethylation, 5 major responses were observed. Treatment was well tolerated by most patients with the most common drug-related adverse events being expected myleosuppression, and Grade 1 injection site pain. The data was presented at an oral session at the ASH 54th Annual Meeting in Atlanta, Georgia.
Volume and pps should start to move up going into next week.
6:01AM Astex Pharma announces oral presentation of SGI-110 results from Phase 1/2 MDS and AML study at ASH; SGI-110 is well tolerated at doses higher than the biologically effective dose (ASTX) 2.24 : Co announced that results from the dose escalation part of a randomized Phase 1/2 first-in-human clinical trial of subcutaneous SGI-110, a novel hypomethylating agent, in patients with relapsed/refractory intermediate or high-risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML) will be presented during the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia on Dec 10, 2012. The dose escalation part of the study demonstrated that SGI-110 is well tolerated at doses higher than the biologically effective dose; subcutaneous administration achieved efficient conversion to decitabine resulting in an improved pharmacokinetic profile over intravenous Dacogen formulation; and clinical responses were observed in this heavily pretreated population which seem to correlate with the extent of LINE-1 hypomethylation.
6:28AM On The Wires (WIRES) :Astex Pharmaceuticals (ASTX) has initiated an open label, randomized, controlled, multi-center, Phase 2 clinical trial, evaluating HSP90 inhibitor AT13387 in anaplastic lymphoma kinase positive non-small cell lung cancer patients or other potentially crizotinib-sensitive NSCLC patients who have been receiving crizotinib.
6:01AM Pharma publish the discovery of novel allosteric modulators for the key therapeutic targets HCV NS3 and PKM2 in nature journals (ASTX) 2.90 : Astex Pharmaceuticals used the company's leading fragment-based drug discovery platform, Pyramid, to identify, in two separate studies, new allosteric pockets on the HCV NS3 protein and the PKM2 protein involved in tumor metabolism. The study on HCV NS3 which has just been published in Nature Chemical Biology1 highlights the discovery of a novel allosteric pocket situated between the protease and helicase domains of the NS3 protein. It also describes how Astex scientists exploited this pocket to develop novel, first-in-class inhibitors of the HCV NS3 protein that interact with both the protease and helicase domains. A drug candidate from this program is due to enter clinical trials during 2013. In the second study, now published in Nature2, the Pyramid platform was used to identify a novel allosteric pocket on the tumor metabolism target PKM2 and unravel the role of serine on the function of this key cancer target.
6:01AM Astex Pharma earns $5 mln for first commercial sale of DACOGEN in the European Union (ASTX) 2.87 : Co announced that a $5 mln milestone was earned from Eisai Inc., for the first commercial sale of DACOGEN in the European Union. Astex receives royalties from Eisai on the global sales of DACOGEN for any indication starting at 20% and escalating to a maximum of 30%. In accordance with Astex's license agreement with Eisai, Astex may receive up to $12.5 mln in future payments if additional milestones are achieved for DACOGEN globally.
6:21AM Astex Pharma: DACOGEN approved in the European Union for the treatment of acute myeloid leukemia (ASTX) 3.10 : Co announced that Janssen-Cilag International NV of Johnson & Johnson (JNJ) was notified that the European Commission has approved the marketing authorization for DACOGEN (decitabine) for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukemia, according to the World Health Organization classification, who are not candidates for standard induction chemotherapy. DACOGEN also has been granted Orphan Drug designation for the treatment of AML.
Congrats to all that held for EU Approval on Dacogen for use AML.
http://www.streetinsider.com/Press+Releases/DACOGEN%C2%AE+Approved+in+the+European+Union+for+the+Treatment+of+Acute+Myeloid+Leukaemia/7756317.html
Waiting patiently for EU Approval on Dacogen AML.
http://www.businessweek.com/news/2012-08-21/astex-climbs-on-expected-european-approval-san-francisco-mover
6:01AM Astex Pharma discontinues Amuvatinib clinical development program (ASTX) 3.33 : Co announced that clinical development of amuvatinib, a multi-targeted tyrosine kinase inhibitor that inhibits the mutant forms of c-Kit and PDGFR alpha and disrupts DNA repair likely through suppression of homologous recombination protein Rad51, has been discontinued. Amuvatinib was being investigated in the Phase 2 ESCAPE study. The study used a Simon 2-stage design with the primary objective in stage 1 of excluding the statistical probability with 90% confidence that the drug has less than 10% response rate in platinum refractory small cell lung cancer patients. Response evaluation by RECIST criteria showed 2 partial responses in the 21 evaluable patients of stage 1. No new safety issues were identified, and biological markers studies are ongoing. There were several patients with prolonged stable disease. The results will be presented in a future scientific meeting.
6:17AM On The Wires (WIRES) Astex Pharmaceuticals (ASTX) has initiated a clinical trial with HSP90 inhibitor AT13387 in prostate cancer patients. The AT13387-04 study is a Phase 1-2, open label, randomized study in patients with castration-resistant prostate cancer who are no longer responding to treatment with standard of care therapies abiraterone acetate and steroids
9:33AM Astex Pharma, Cancer Research Technology and The Institute of Cancer Research announce epigenetic drug discovery collaboration (ASTX) 3.06 -0.01 : "Putting in place this collaboration between the Cancer Research UK-funded drug discovery team at the ICR and Astex provides a powerful route to identify drug candidates for this promising new target. "The deal will ensure that the research programme benefits from the necessary investment to progress the research to its full potential while building on the validation and assay development work that has been carried out at the ICR and funded by Cancer Research UK and others."
Astex Pharmaceuticals to Present at September Investor Conferences
DUBLIN, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) — Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that members of its senior management team will present at the following investor conferences in September:
Stifel Nicolaus Healthcare Conference
Thursday, September 6 at 10:55 am ET
Boston, MA
BioCentury and Thomson Reuters’ NewsMakers in the Biotech Industry
Friday, September 7 at 10:00 am ET
New York, NY
Rodman & Renshaw Global Investment Conference
Monday, September 10 at 11:40 am ET
New York, NY
Webcast information and presentation materials will be available in the Investor Events section of the Company’s website, www.astx.com. Both will be archived for 30 days.
ASTX Video Chart 8/13/2012
http://www.missionir.com/videos.html
6:01AM Astex Pharma earns $5.4 mln milestone on Phase I trial initiation of a FGFR kinase inhibitor (ASTX) 1.82 : Co announces that Janssen Pharmaceutical has received clearance to commence a Phase I clinical trial of a Fibroblast Growth Factor Receptor kinase inhibitor from its collaborative, cancer drug discovery program with Astex. The regulatory approval required to take the compound into Phase I triggers a milestone payment to ASTX of GBP3.5 mln ($5.4 mln). ASTX is also eligible to receive further milestones during clinical development and royalties on commercialization of products derived from the collaboration.
Good overview. A couple quick clarifications.
Imatinib is not a hypomethylating agent. SGI-110 is a prodrug of DACOGEN (decitabine). The other marketed hypomthylator is VIDAZA (5-azacytidine) from CELG
SGI-110 was not a product of the CLIMB discovery platform used by Supergen (which I concur was a complete bust)
AT13387 and all other current ASTX pipeline assets not mentioned in your previous post are derived from the Astex Therapeutics Ltd fragment-based discovery pipeline.
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
217
|
Created
|
07/16/07
|
Type
|
Free
|
Moderators |
http://astx.com/
http://www.supergen.com/
http://finance.yahoo.com/q/ks?s=astx
http://www.secform4.com/insider-trading/919722.htm
SuperGen, Inc., a pharmaceutical company, engages in the discovery, acquisition, development, and commercialization of therapies to treat patients with cancer. It offers Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites. The company also involves in developing various therapeutic anticancer products focused on inhibitors of aurora-A, tyrosine kinase, and DNA methyltransferase. Its generic anti cancer products include Mitomycin and Paclitaxel for solid tumors. The company's formulation products include Mitozytrex; Partaject busulfan for neoplastic meningitis/bone marrow transplant in Phase I/II; Partaject Orathecin and Cremophor-free paclitaxel for solid tumors in pre clinical stage; and CZ 112 for solid tumors in Phase I. SuperGen's other product candidates include Avicine, a therapeutic vaccine in Phase II; and VEGF, an anti angiogenesis in pre clinical stage. It has collaborations with MGI PHARMA, Inc.; The Stehlin Foundation for Cancer Research; Warner-Lambert Company; Peregrine Pharmaceuticals; AVI BioPharma, Inc.; and University of Arizona. The company sells its products to clinics, hospitals, and hospital buying groups in the United States, as well as to drug distributors and wholesalers in the United States and Europe. SuperGen was founded in 1991 and is headquartered in Dublin, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |